Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets.

Gao J, Chang MT, Johnsen HC, Gao SP, Sylvester BE, Sumer SO, Zhang H, Solit DB, Taylor BS, Schultz N, Sander C.

Genome Med. 2017 Jan 23;9(1):4. doi: 10.1186/s13073-016-0393-x.

2.

Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.

Okimoto RA, Lin L, Olivas V, Chan E, Markegard E, Rymar A, Neel D, Chen X, Hemmati G, Bollag G, Bivona TG.

Proc Natl Acad Sci U S A. 2016 Nov 22;113(47):13456-13461.

PMID:
27834212
3.

Real-time tests of multiple genome alterations take the first steps into the clinic: a learning example.

Gerratana L, De Maglio G, De Pellegrin A, Follador A, Rihawi K, Pizzolitto S, Puglisi F, Fasola G.

Onco Targets Ther. 2016 Aug 30;9:5399-404. doi: 10.2147/OTT.S104748.

4.

Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer.

Broutin S, Stewart A, Thavasu P, Paci A, Bidart JM, Banerji U.

Br J Cancer. 2016 Aug 23;115(5):549-52. doi: 10.1038/bjc.2016.220.

5.

Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.

Kim JY, Welsh EA, Fang B, Bai Y, Kinose F, Eschrich SA, Koomen JM, Haura EB.

Mol Cancer Res. 2016 Oct;14(10):1019-1029.

PMID:
27422710
6.

Non-small cell lung cancer: current treatment and future advances.

Zappa C, Mousa SA.

Transl Lung Cancer Res. 2016 Jun;5(3):288-300. doi: 10.21037/tlcr.2016.06.07. Review.

7.

Negative feedback regulation of the ERK1/2 MAPK pathway.

Lake D, Corrêa SA, Müller J.

Cell Mol Life Sci. 2016 Dec;73(23):4397-4413. Review.

8.

Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC.

Bansal P, Osman D, Gan GN, Simon GR, Boumber Y.

Front Oncol. 2016 May 4;6:112. doi: 10.3389/fonc.2016.00112. Review.

9.
10.

Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis.

Crago AM, Chmielecki J, Rosenberg M, O'Connor R, Byrne C, Wilder FG, Thorn K, Agius P, Kuk D, Socci ND, Qin LX, Meyerson M, Hameed M, Singer S.

Genes Chromosomes Cancer. 2015 Oct;54(10):606-15. doi: 10.1002/gcc.22272.

11.

Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK.

Rothschild SI.

Cancers (Basel). 2015 May 26;7(2):930-49. doi: 10.3390/cancers7020816. Review.

12.

BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors.

Sánchez-Torres JM, Viteri S, Molina MA, Rosell R.

Transl Lung Cancer Res. 2013 Jun;2(3):244-50. doi: 10.3978/j.issn.2218-6751.2013.04.01. Review.

13.

Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.

Joshi M, Rice SJ, Liu X, Miller B, Belani CP.

PLoS One. 2015 Feb 23;10(2):e0118210. doi: 10.1371/journal.pone.0118210.

14.

Increased BRAF copy number in lung adenocarcinoma.

Sasaki H, Maekawa M, Tatematsu T, Okuda K, Moriyama S, Yano M, Fujii Y.

Oncol Lett. 2015 Feb;9(2):709-712.

15.

By downregulating Ku80, hsa-miR-526b suppresses non-small cell lung cancer.

Zhang ZY, Fu SL, Xu SQ, Zhou X, Liu XS, Xu YJ, Zhao JP, Wei S.

Oncotarget. 2015 Jan 30;6(3):1462-77.

16.

MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.

Arcila ME, Drilon A, Sylvester BE, Lovly CM, Borsu L, Reva B, Kris MG, Solit DB, Ladanyi M.

Clin Cancer Res. 2015 Apr 15;21(8):1935-43. doi: 10.1158/1078-0432.CCR-14-2124.

17.

Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives.

Cheng X, Chen H.

Onco Targets Ther. 2014 Sep 23;7:1689-704. doi: 10.2147/OTT.S66502. Review.

18.

Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions.

Brannon AR, Vakiani E, Sylvester BE, Scott SN, McDermott G, Shah RH, Kania K, Viale A, Oschwald DM, Vacic V, Emde AK, Cercek A, Yaeger R, Kemeny NE, Saltz LB, Shia J, D'Angelica MI, Weiser MR, Solit DB, Berger MF.

Genome Biol. 2014 Aug 28;15(8):454. doi: 10.1186/s13059-014-0454-7.

19.

Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification.

Jang WJ, Jung SK, Kang JS, Jeong JW, Bae MK, Joo SH, Park GH, Kundu JK, Hong YS, Jeong CH.

Cancer Sci. 2014 Oct;105(10):1245-53. doi: 10.1111/cas.12497.

20.

Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer.

Beck TN, Chikwem AJ, Solanki NR, Golemis EA.

Physiol Genomics. 2014 Oct 1;46(19):699-724. doi: 10.1152/physiolgenomics.00062.2014. Review.

Supplemental Content

Support Center